Exscientia vs SigTuple

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Exscientia employs 100-500 people, while SigTuple has 100-500 employees.

Exscientia has raised more in total funding at $500M, compared to SigTuple's $20M — a gap of $480M.

Exscientia holds the higher Awaira Score at 72/100, compared to SigTuple's 60/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 12-point gap that reflects meaningful differences in scale or traction.

Exscientia was founded by Andrew Hopkins in 2012. SigTuple was founded by Rohit Kumar Pandey in 2015. Visit each company's profile on Awaira for a full founder biography.

Exscientia: Exscientia is an AI-driven drug design company that uses automated design-make-test-analyse cycles to generate drug candidates with the goal of reducing the time and cost of small molecule drug discovery. The Oxford-originated company builds generative chemistry models and automated laboratory robotics that together create a closed-loop system for molecular design, synthesis, and assay testing, producing candidates in months rather than the years required by conventional medicinal chemistry programmes.\n\nThe company went public on NASDAQ under the ticker EXAI, having raised over $500 million in combined public and private funding from investors including Bristol-Myers Squibb, Celgene, SoftBank, and GT Healthcare Capital Partners. Exscientia has clinical-stage programmes in oncology and neuropsychiatry and reports being the first company to advance AI-designed drug candidates into human clinical trials. The company has multiple pharma partnerships including agreements with Bristol-Myers Squibb, Sanofi, and Evotec that provide milestone and royalty revenue.\n\nExscientia competes in the AI drug design space against Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics, and Insilico Medicine. The company differentiates through its integrated automated laboratory approach, which combines computational design with physical synthesis and testing in a single workflow rather than treating AI design as a separate step before conventional chemistry. Its public market position and disclosed clinical programmes provide transparency benchmarks against which the broader AI drug discovery sector is measured by investors and pharmaceutical partners. SigTuple: SigTuple develops AI-powered automated pathology solutions that digitize and analyze microscopy slides for blood, urine, sputum, and semen samples, enabling high-throughput diagnostic testing without the constant presence of trained pathologists. The company's AI-Minth platform uses robotic sample preparation, high-resolution imaging, and deep learning analysis to deliver diagnostic-grade results.\n\nThe company raised approximately $20M in Series B funding and has deployed its automated microscopy systems at diagnostic labs, hospitals, and blood banks across India, processing millions of diagnostic samples. SigTuple has received regulatory approvals for its diagnostic AI products and has established partnerships with major diagnostic laboratory chains.\n\nIndia faces a severe shortage of qualified pathologists relative to population, creating an acute need for AI-assisted diagnostic automation. SigTuple's approach of combining hardware, robotics, and AI in an integrated system addresses the complete diagnostic workflow rather than just the software layer, creating higher deployment barriers but also higher switching costs and stronger network effects from accumulated diagnostic data.

Exscientia was founded first in 2012, giving it 3 years of additional market experience. SigTuple was founded later in 2015. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Both Exscientia and SigTuple report similar employee counts of approximately 100-500. Team size is often a proxy for operational scale, though lean AI companies can punch well above their headcount.

Yes, Exscientia and SigTuple are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.